Established at the Montreal Heart Institute, MONOGENIC has an experienced management team supported by leading scientific and clinical experts in the field of PCSK9, lipid metabolism and ASCVD.
Over 20 million person-years of follow-up and over 150 000 cardiovascular events unequivocally demonstrated a direct causal link between LDL-Cholesterol and ASCVD.
MONOGENIC Pharmaceuticals is developing innovative and disruptive orally available small molecules to control atherosclerotic cardiovascular disease (ASCVD) by helping the body to clear excess LDL-Cholesterol.
MONOGENIC is grateful to the Montreal Heart Institute as its institutional partner.
We are currently seeking for private partners to complete our Series A and R&D Program (pre-IND and Phase 1) with interest in advancing to and completion of Phase 2.